Healthcare

01:22

                            BGI: Net loss of 52.6951 million yuan in the first quarter of 2025
                        
                            BGI announced that its operating income in the first quarter of 2025 was 672 million yuan, a year-on-year decrease of 18.18%. Its net loss was 52.6951 million yuan, compared with a net profit of 12.4025 million yuan in the same period last year.
                        
16:55

                            Pfizer: Axitinib is approved as the first and only first-line target-immune combination therapy for advanced renal cancer in China
                        
                            On April 25, Pfizer announced that its oral targeted drug Inlyta (generic name: axitinib tablets) was approved by the National Medical Products Administration (NMPA) on April 22, 2025, combined with toripalimab for the first-line treatment of patients with intermediate- and high-risk unresectable or metastatic renal cell carcinoma (RCC). According to it, this is also the first and only first-line target-immune combination therapy approved in the field of renal cancer treatment in China.
                        
13:48

                            The A-share pharmaceutical sector continued to rise in the afternoon, and innovative drugs continued to lead the gains. Zhongsheng Pharmaceutical, Watson Pharmaceuticals, and Fujilife hit their daily limit, while Baili Tianheng, InnoCare Pharma, Sinopharm, and BeiGene hit historical highs. Fudan Zhangjiang, Shanghai YiZhong, Salidome, and Regeneron Biopharma were among the top gainers.
                        
13:35

                            Hong Kong stocks' innovative drug sector continued to strengthen in the afternoon, with Innovent Biologics rising by more than 10%
                        
                            The Hong Kong stock market's innovative drug sector continued to strengthen in the afternoon, with Innovent Biologics and Innovent Biologics rising by more than 10%, BeiGene rising by nearly 10%, and CSPC Pharmaceutical Group, Rongchang Biopharma, and WuXi Biologics all rising sharply.
                        
12:01

                            Hong Kong Stocks Midday Review: Hang Seng Index fell 0.04%, Hang Seng Technology Index fell 0.5%
                        
                            At the close of Hong Kong stocks at noon, the Hang Seng Index fell 0.04% and the Hang Seng Technology Index fell 0.5%. Gold and innovative drug sectors led the gains. Chifeng Gold and Shandong Gold rose more than 10%; Ascletis Pharmaceuticals-B rose nearly 20%, and WuXi Biologics rose more than 3%. Tongcheng Travel fell nearly 10%.
                        
09:51

                            The Hong Kong stock market's innovative drug sector strengthened, with Ascletis Pharmaceuticals (01672.HK) rising more than 20%, Rongchang Biopharma (09995.HK) and CSPC Pharmaceutical Group (01093.HK) rising more than 6%, and BeiGene (06160.HK) and Innovent Biologics (01801.HK) following suit.
                        
09:44

                            Hong Kong stocks' innovative drug sector surged in early trading, with Ascletis Pharmaceuticals-B up more than 20%
                        
                            The Hong Kong stock market's innovative drug sector surged in early trading, with Ascletis Pharmaceuticals-B rising more than 20%, Rongchang Biopharma and CSPC Pharmaceutical Group rising more than 6%, BeiGene and Innovent Biologics rising more than 3%.
                        
19:19

                            Eli Lilly CEO: Conduct research on Alzheimer's disease prevention and other brain diseases
                        
                            Eli Lilly's CEO said that research on Alzheimer's disease prevention and other brain diseases will be carried out.
                        
19:16

                            Eli Lilly CEO: It's important that we don't raise drug prices.
                        
                            Eli Lilly's CEO said it's important that they don't raise drug prices.
                        
16:14

                            Morgan Stanley: Orforglipron, an oral weight loss drug, has become a driving force for stock prices, and Eli Lilly can still rise by another 34%
                        
                            Morgan Stanley said that the oral weight loss drug Orforglipron has become a driving force for the stock price, and Eli Lilly can still rise by another 34%.
                        
09:27

                            Most of the A-share weight loss drug sectors opened higher, with Kingchem Biosciences rising more than 10%, Huadong Medicine rising more than 4%, and Hanyu Pharmaceutical and Baihua Pharmaceutical following suit.
                        
09:27

                            Diet drug concept stocks were active at the beginning of trading, and Jinkai Biosciences rose by more than 10%
                        
                            Weight loss drug concept was active at the beginning of the session, with Jinkai Biosciences rising more than 10%, followed by Haofan Bio, Huadong Medicine, Hanyu Pharmaceutical, Baihua Pharmaceutical, Yipinhong, Changshan Pharmaceutical, etc. On the news front, Eli Lilly's oral weight loss drug Orforglipron had impressive Phase III clinical data, and its stock price rose by more than 14%.
                        
21:38

                            Novo Nordisk fell 8% in early trading
                        
                            Novo Nordisk fell 8% in early trading after its weight loss drug competitor Eli Lilly achieved positive results in a Phase 3 trial of an oral weight loss drug.
                        
21:30

                            U.S. stocks open: three major indexes rise and fall, Dow opens more than 1% lower
                        
                            At the opening of the US stock market, the Dow Jones Industrial Average fell 1.23%, the S&P 500 rose 0.35%, and the Nasdaq rose 0.53%. TSMC rose more than 2%, and its Q1 net profit increased by 60% year-on-year, exceeding expectations. Eli Lilly rose 14%. The company released data on its weight loss drug study, and participants lost an average of 16 pounds at the highest dose. UnitedHealth fell 17% as the company lowered its annual profit forecast.
                        
19:25

                            BMO: Lowered Pfizer (PFE.N) price target to $30 from $36.
                        
1745601728
114688
3

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Trends

AI AI Tesla bitcoin Xiaomi Alibaba Nvidia Tencent Huawei Apple

Weekly Highlights

                                    Hong Kong Stock Midday Review: Hang Seng Index fell 1.21%, Hang Seng Technology Index fell 2.04%
                            2025-04-24

                                    Tesla's gains in US stocks expanded to 5%
                            2025-04-22

                                    BYD: Net profit in the first quarter increased by 100.38%
                            2025-04-25

                                    Intel fell nearly 4% on the Frankfurt exchange
                            2025-04-25

                                    Chinese AI startup MANUS raises funding at nearly $500 million valuation
                            2025-04-25